Gor Dhairya, Mehta Rohan, Greenberg David, Angelova Evgeniya
Internal Medicine Department, Jersey Shore Medical Center, Neptune, NJ, USA.
Hematology Oncology Department, Jersey Shore Medical Center, Neptune, NJ, USA.
Eur J Case Rep Intern Med. 2022 Jul 7;9(7):003463. doi: 10.12890/2022_003463. eCollection 2022.
It is rare for IgM multiple myeloma (MM) and mantle cell lymphoma (MCL) to coexist. Furthermore, it is challenging to demonstrate if there are two distinct types of neoplasia or if plasma cell differentiation of MCL is present. We discuss the case of a patient concomitantly diagnosed with MCL and IgM MM, and the subsequent diagnostic and management difficulties, and the positive treatment outcome.
Due to the rarity of simultaneous multiple myeloma (MM) and mantle cell lymphoma (MCL), it is challenging to investigate a possible association.This report will draw attention to the condition's rarity, diagnostic and treatment hurdles, and hopefully inspire future research into therapeutic alternatives.Several recent developments indicate a bright future for treating refractory malignancies such as MM and MCL, such as the advent of chimeric antigen receptor T-cell (CAR T-cell) therapy.
IgM型多发性骨髓瘤（MM）与套细胞淋巴瘤（MCL）共存的情况罕见。此外，要证明是否存在两种不同类型的肿瘤形成或MCL是否存在浆细胞分化具有挑战性。我们讨论了一例同时诊断为MCL和IgM MM的患者病例、随后的诊断和管理困难以及积极的治疗结果。
由于同时发生多发性骨髓瘤（MM）和套细胞淋巴瘤（MCL）的情况罕见，因此研究可能的关联具有挑战性。本报告将提请注意该疾病的罕见性、诊断和治疗障碍，并有望激发未来对治疗替代方案的研究。最近的几项进展表明，治疗MM和MCL等难治性恶性肿瘤前景光明，例如嵌合抗原受体T细胞（CAR T细胞）疗法的出现。
